EU/3/14/1425: Orphan designation for the treatment of spinocerebellar ataxia

Ceftriaxone

Overview

On 15 January 2015, orphan designation (EU/3/14/1425) was granted by the European Commission to Ospedale San Raffaele s.r.l., Italy, for ceftriaxone for the treatment of spinocerebellar ataxia.

Key facts

Active substance
Ceftriaxone
Intented use
Treatment of spinocerebellar ataxia
Orphan designation status
Positive
EU designation number
EU/3/14/1425
Date of designation
15/01/2015
Sponsor
Ospedale San Raffaele s.r.l.
Via Olgettina, 60
20132 Milan
Italy
Tel. +39 02 26 43 35 02
Fax +39 02 26 43 63 52
E-mail: casari.giorgio@hsr.it

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating